The multidisciplinary Southampton team, led by Dr Jessica Teeling, and in collaboration with Lundbeck (a multinational pharmaceutical company based in Denmark), engineered three antibodies to change the way
they engage cells in the immune system.
Dr. Levitsky: My organization within Roche, Pharma Research and Early Development (pRED), has invested
in antibody engineering, not only for use of monoclonal antibodies
in the established ways of delivering
cell - killing agents to tumors or interrupting
cell signalling pathways, but also as ways to
engage and manipulate the
immune system's response to tumors.